Search Results Search Sort by RelevanceMost Recent Case and Commentary Jan 2005 No Students Please, Option Comparison Karine Morin, LLM Virtual Mentor. 2005;7(1):43-47. doi: 10.1001/virtualmentor.2005.7.1.ccas8b-0501. Case and Commentary Jan 2005 No Students Please, Additional Information Karine Morin, LLM Virtual Mentor. 2005;7(1):43-47. doi: 10.1001/virtualmentor.2005.7.1.ccas8c-0501. Case and Commentary Jan 2005 An Inoperable Cancer Option Assessment Faith Lagay, PhD Virtual Mentor. 2005;7(1):74-79. doi: 10.1001/virtualmentor.2005.7.1.ccas13a-0501. Case and Commentary Jan 2005 An Inoperable Cancer, Option Comparison Faith Lagay, PhD Virtual Mentor. 2005;7(1):74-79. doi: 10.1001/virtualmentor.2005.7.1.ccas13b-0501. Case and Commentary Jan 2005 An Inoperable Cancer, Additional Information Faith Lagay, PhD Virtual Mentor. 2005;7(1):68-73. doi: 10.1001/virtualmentor.2005.7.1.ccas13c-0501. Case and Commentary Jan 2005 Mrs. Scott's Plan for the Future, Option Assessment Jennifer Reenan, MD Virtual Mentor. 2005;7(1):80-86. doi: 10.1001/virtualmentor.2005.7.1.ccas14a-0501. Case and Commentary Jan 2005 Mrs. Scott's Plan for the Future, Option Comparison Jennifer Reenan, MD Virtual Mentor. 2005;7(1):80-86. doi: 10.1001/virtualmentor.2005.7.1.ccas14b-0501. Case and Commentary Jan 2005 Mrs. Scott's Plan for the Future, Additional Information Jennifer Reenan, MD Virtual Mentor. 2005;7(1):80-86. doi: 10.1001/virtualmentor.2005.7.1.ccas14c-0501. In the Literature Feb 2010 Risks and Benefits of Innovative Off-Label Surgery Caitlin E. Weber Controversy associated with off-label application of drugs and devices has arisen as innovative treatments clash with responsible regulation. Virtual Mentor. 2010;12(2):97-101. doi: 10.1001/virtualmentor.2010.12.2.jdsc1-1002. Case and Commentary Feb 2010 Technical Skill and Informed Consent Robert M. Sade, MD Does a surgeon’s complication rate in a randomized controlled trial constitute a “significant new finding” that must be reported to patients during the consent process? Virtual Mentor. 2010;12(2):87-90. doi: 10.1001/virtualmentor.2010.12.2.ccas3-1002. Pagination First page « First Previous page ‹ Previous … Page 15 Page 16 Page 17 Page 18 Page 19 Current page 20 Page 21 Page 22 Page 23 Next page Next › Last page Last »
Case and Commentary Jan 2005 No Students Please, Option Comparison Karine Morin, LLM Virtual Mentor. 2005;7(1):43-47. doi: 10.1001/virtualmentor.2005.7.1.ccas8b-0501.
Case and Commentary Jan 2005 No Students Please, Additional Information Karine Morin, LLM Virtual Mentor. 2005;7(1):43-47. doi: 10.1001/virtualmentor.2005.7.1.ccas8c-0501.
Case and Commentary Jan 2005 An Inoperable Cancer Option Assessment Faith Lagay, PhD Virtual Mentor. 2005;7(1):74-79. doi: 10.1001/virtualmentor.2005.7.1.ccas13a-0501.
Case and Commentary Jan 2005 An Inoperable Cancer, Option Comparison Faith Lagay, PhD Virtual Mentor. 2005;7(1):74-79. doi: 10.1001/virtualmentor.2005.7.1.ccas13b-0501.
Case and Commentary Jan 2005 An Inoperable Cancer, Additional Information Faith Lagay, PhD Virtual Mentor. 2005;7(1):68-73. doi: 10.1001/virtualmentor.2005.7.1.ccas13c-0501.
Case and Commentary Jan 2005 Mrs. Scott's Plan for the Future, Option Assessment Jennifer Reenan, MD Virtual Mentor. 2005;7(1):80-86. doi: 10.1001/virtualmentor.2005.7.1.ccas14a-0501.
Case and Commentary Jan 2005 Mrs. Scott's Plan for the Future, Option Comparison Jennifer Reenan, MD Virtual Mentor. 2005;7(1):80-86. doi: 10.1001/virtualmentor.2005.7.1.ccas14b-0501.
Case and Commentary Jan 2005 Mrs. Scott's Plan for the Future, Additional Information Jennifer Reenan, MD Virtual Mentor. 2005;7(1):80-86. doi: 10.1001/virtualmentor.2005.7.1.ccas14c-0501.
In the Literature Feb 2010 Risks and Benefits of Innovative Off-Label Surgery Caitlin E. Weber Controversy associated with off-label application of drugs and devices has arisen as innovative treatments clash with responsible regulation. Virtual Mentor. 2010;12(2):97-101. doi: 10.1001/virtualmentor.2010.12.2.jdsc1-1002.
Case and Commentary Feb 2010 Technical Skill and Informed Consent Robert M. Sade, MD Does a surgeon’s complication rate in a randomized controlled trial constitute a “significant new finding” that must be reported to patients during the consent process? Virtual Mentor. 2010;12(2):87-90. doi: 10.1001/virtualmentor.2010.12.2.ccas3-1002.